NEW ORLEANS — In this Healio Video Perspective from the Eyecelerator meeting, Ben Yerxa, PhD, acting CEO of Opus Genetics, discusses the company’s plans, including the beginning of trials of OPGx-001, designed to target the LCA5 gene.
Uncategorized
VIDEO: Opus Genetics plans to bring therapies for rare retinal diseases to clinical trials